Ellipsis Health
Voice AI care management for health plans and at risk providers, originating in vocal biomarker research for detecting depression and anxiety and now productized as Sage, an AI care manager. The distinguishing technical claim is the Empathy Engine, patented vocal biomarker technology trained on millions of live clinical patient calls, which reads emotional state from voice in real time rather than only transcribing words, and adapts tone and approach accordingly. Sage conducts inbound and outbound member calls covering health risk assessments, post discharge follow up, risk profiling, care gap closure, program enrollment, medication reminders, and triage, and is positioned explicitly as added staffing capacity rather than a chatbot, reserving clinicians for complex high touch interventions. Integrations include Salesforce Health Cloud and, through an April 2026 partnership with HealthEdge, the Care Solutions suite drawing on GuidingCare member data and returning outcomes to the platform. Company reported figures, which it acknowledges are not independently audited, include roughly 60 percent reduction in administrative tasks, 6x faster program enrollment, and 4x return on investment. Named customers per the company website include UnitedHealth Group, Aetna, Duke Health, and Highmark. Founded 2017 by CEO Mainul Mondal; approximately $75 million raised including a $45 million round in June 2025 co-led by Salesforce, Khosla Ventures, and CVS Health Ventures.
Capability Axes
Vocal biomarker analysis is the product and the company's origin: the technology began as research into detecting depression and anxiety from voice, and Sage applies it during live calls to read emotional state and adapt. That is inference on the acoustic signal rather than on the transcript, which is a materially different capability from the other voice agents in this index.
Positioning is consistent and correct in shape: added staffing capacity rather than a chatbot, with the explicit purpose of reserving skilled clinicians for complex, high touch interventions while the agent handles high volume outreach. Held back from A because escalation criteria are not published, and the gap matters given what the system detects: if vocal analysis surfaces acute distress or crisis signal during a routine care gap call, the handoff protocol is the single most important control and it is undisclosed.
The training basis is stated specifically: a patented Empathy Engine trained on millions of live clinical patient calls, with vocal biomarker work grounded in published research on detecting mental health conditions from voice. Held back from A because no accuracy, sensitivity, or specificity figures for the emotional or mental health inference were retrieved, and this is precisely the axis where a vocal biomarker claim needs numbers. Detecting depression from voice is a strong claim and should be evidenced as one.
Distribution and investor signals are strong: a strategic HealthEdge partnership embedding Sage into Care Solutions with GuidingCare member data, Salesforce Health Cloud integration, and CVS Health Ventures participating in the funding round. Named customers per the company website include UnitedHealth Group, Aetna, Duke Health, and Highmark. Held back because the operational figures, roughly 60 percent administrative task reduction, 6x faster enrollment, and 4x return on investment, are acknowledged by third party review as company reported and not independently audited, and no clinical validation of the biomarker capability in deployment was retrieved.
The most sensitive inference surface among the voice agents in this index, and disclosure does not match it. The system infers emotional and mental health state from vocal characteristics during routine care management calls, which means it may derive behavioural health signal from members who called about something else and never consented to a mental health assessment. No disclosure was retrieved covering member notification, consent for biomarker analysis, retention of voice recordings, or how inferred mental health signals are stored and shared with the plan. When those signals return to a health plan alongside member data, the stakes are higher than for transcription.
No public pricing. Contact the vendor. Sold to health plans, at risk providers, and care management organizations, increasingly through platform partners including HealthEdge and Salesforce, which means some buyers will encounter it as a component of a larger contract rather than a standalone purchase. Worth establishing whether the biomarker capability is separately priced or bundled.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Health plan and care management agreements; also sold via platform partners | — | — | Third Party Estimated |
No rate card published. Sold to health plans, at risk providers, and care management organizations. Increasingly distributed through platform partnerships including HealthEdge Care Solutions and Salesforce Health Cloud, so some buyers will meet it embedded in a larger platform contract rather than as a direct purchase. Reported returns of roughly 4x and 60 percent administrative task reduction are company stated and, per third party review, not independently audited, so they should be treated as a starting point for diligence rather than a basis for a business case.